JOP20220097A1 - كريزانليزوماب يحتوي على صياغات اجسام مضادة - Google Patents

كريزانليزوماب يحتوي على صياغات اجسام مضادة

Info

Publication number
JOP20220097A1
JOP20220097A1 JOP/2022/0097A JOP20220097A JOP20220097A1 JO P20220097 A1 JOP20220097 A1 JO P20220097A1 JO P20220097 A JOP20220097 A JO P20220097A JO P20220097 A1 JOP20220097 A1 JO P20220097A1
Authority
JO
Jordan
Prior art keywords
krizanlizumab
antibody formulations
contains antibody
formulations
antibody
Prior art date
Application number
JOP/2022/0097A
Other languages
Arabic (ar)
English (en)
Inventor
Juergen Sigg
Maja Anko
Lina Boado
Rajsekhar Paul
Fabian Bickel
Aljosa Jelenko
Francois Griaud
Frieder Kroener
Dirk Chelius
Caroline Hilbert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20220097A1 publication Critical patent/JOP20220097A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JOP/2022/0097A 2019-10-30 2022-04-27 كريزانليزوماب يحتوي على صياغات اجسام مضادة JOP20220097A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962927720P 2019-10-30 2019-10-30
US201962927716P 2019-10-30 2019-10-30
US201962933692P 2019-11-11 2019-11-11
US201962936269P 2019-11-15 2019-11-15
PCT/US2020/057868 WO2021087050A1 (en) 2019-10-30 2020-10-29 Crizanlizumab containing antibody formulation

Publications (1)

Publication Number Publication Date
JOP20220097A1 true JOP20220097A1 (ar) 2023-01-30

Family

ID=73544317

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0097A JOP20220097A1 (ar) 2019-10-30 2022-04-27 كريزانليزوماب يحتوي على صياغات اجسام مضادة

Country Status (19)

Country Link
US (1) US20220378912A1 (cg-RX-API-DMAC7.html)
EP (1) EP4051236A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023501155A (cg-RX-API-DMAC7.html)
KR (1) KR20220092917A (cg-RX-API-DMAC7.html)
CN (1) CN114828826A (cg-RX-API-DMAC7.html)
AU (1) AU2020373017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022008097A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158921A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001085A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005207A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22033601A (cg-RX-API-DMAC7.html)
IL (1) IL292403A (cg-RX-API-DMAC7.html)
JO (1) JOP20220097A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022005044A (cg-RX-API-DMAC7.html)
MY (1) MY209141A (cg-RX-API-DMAC7.html)
PE (1) PE20221276A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551041A1 (cg-RX-API-DMAC7.html)
TW (1) TWI893018B (cg-RX-API-DMAC7.html)
WO (1) WO2021087050A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
RU2020132460A (ru) * 2018-03-08 2022-04-08 Новартис Аг Применение антитела к p-селектину

Also Published As

Publication number Publication date
JP2023501155A (ja) 2023-01-18
TWI893018B (zh) 2025-08-11
MX2022005044A (es) 2022-05-16
CO2022005207A2 (es) 2022-05-10
MY209141A (en) 2025-06-24
CA3158921A1 (en) 2021-05-06
AU2020373017A1 (en) 2022-05-19
PE20221276A1 (es) 2022-09-05
CN114828826A (zh) 2022-07-29
US20220378912A1 (en) 2022-12-01
KR20220092917A (ko) 2022-07-04
ECSP22033601A (es) 2022-05-31
CL2022001085A1 (es) 2023-02-03
WO2021087050A1 (en) 2021-05-06
IL292403A (en) 2022-06-01
EP4051236A1 (en) 2022-09-07
TW202128221A (zh) 2021-08-01
BR112022008097A2 (pt) 2022-08-02
PH12022551041A1 (en) 2023-04-24
AU2020373017B2 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
PH12020550051A1 (en) Glp-1 compositions and uses thereof
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
PH12021550974A1 (en) Stablized pre-fusion rsv f proteins
WO2020097537A3 (en) Fused ring compounds
WO2021021837A3 (en) Anti-pvrig antibodies formulations and uses thereof
EA201991701A1 (ru) Состав на основе моноклонального антитела к rsv
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
MX391339B (es) Composicion farmaceutica que comprende selexipag.
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
MX2022005256A (es) Inhibidores de cd73.
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX2020008125A (es) Composiciones que comprenden berberina.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
EA202192199A1 (ru) Композиции, содержащие коричную кислоту, и способы их применения
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX420767B (es) Proteina de union al factor h modificada
WO2020243572A3 (en) Pan-neuraminidase inhibiting antibodies
WO2018170236A9 (en) CDPK1 INHIBITORS, COMPOSITIONS AND RELATED METHODS
MX2022005044A (es) Formulacion de anticuerpo que contiene crizanlizumab.
EA202090333A1 (ru) Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина
BR112018011590A2 (pt) formulação cosmética